Show simple item record

dc.contributor.authorCocker, HA
dc.contributor.authorHobbs, SM
dc.contributor.authorTiffin, N
dc.contributor.authorPritchard-Jones, K
dc.contributor.authorPinkerton, CR
dc.contributor.authorKelland, LR
dc.date.accessioned2018-09-26T08:32:41Z
dc.date.issued2001-11-30
dc.identifier11
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2001, 85 pp. 1746 - 1752
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2867
dc.identifier.doi10.1054/bjoc.2001.2145
dc.description.abstractThe MDM2 protein is known to be overexpressed in some sarcomas including rhabdomyosarcoma. However, the extent to which the MDM2 protein influences sensitivity to chemotherapeutic drugs is unclear. We have analysed this further using stable transfection of the mdm2 gene into 4 well-characterised human paediatric rhabdomyosarcoma cell lines. Transfection with the mdm2 gene resulted in increased levels of the MDM2 protein in all the cell lines. In 2 of the lines. SCMC and RD, the mdm2 gene caused between 2-fold and 61-fold increase in resistance to vincristine, etoposide and doxorubicin but not to cisplatin. In these lines there was an increase in expression of the mdr-1 gene which encodes P-glycoprotein, but not the mrp1 gene which encodes the multidrug resistance protein (MRP). The resistance was reversible using the MDR modulator PSC833. confirming the presence of P-glycoprotein. We conclude that MDM2 overexpression may be a mechanism by which multidrug resistance is regulated in some rhabdomyosarcomas. (C) 2001 Cancer Research Campaign.
dc.format.extent1746 - 1752
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleHigh levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance
dc.typeJournal Article
rioxxterms.versionofrecord10.1054/bjoc.2001.2145
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2001-11-30
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBRITISH JOURNAL OF CANCER
pubs.notesresearcherid-numbers: pinkerton, ross/I-4808-2014 Tiffin, Nicki/A-5914-2013 Pritchard-Jones, Kathy/F-4286-2014 orcid-numbers: Pritchard-Jones, Kathy/0000-0002-2384-9475 unique-id: ISI:000173054800022
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume85
pubs.embargo.termsNot known
dc.contributor.icrauthorPritchard-Jones, Kathyen
dc.contributor.icrauthorKelland, Lloyden
dc.contributor.icrauthorPinkerton, Rossen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0